Skip to main content

Dr. Jason Brown, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
11
In the NPI registry since
2015
Medicare patients seen, 2024
120

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2015Medical school: Yale University School of Medicine
  • 2015Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    OH license 35.141962
  • Student in an Organized Health Care Education/Training Program
    MI license 4301106976

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
120
Services billed
455
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes18396
New patient office or other outpatient visit, 60-74 minutes3333

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 16 companies reported 55 payments worth $19,978 in total to this clinician.

By type
Consulting Fee$12,991
Compensation for services other than consulting (speaking, faculty)$4,270
Food and Beverage$1,577
Travel and Lodging$1,140

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 4, 2025Merck Sharp & Dohme LLC
Jun 4, 2025
Compensation for services other than consulting (speaking, faculty)
WELIREG · ONCOLOGY
$4,270
Oct 1, 2025AstraZeneca Pharmaceuticals LP
Oct 1, 2025
Consulting Fee
IMFINZI · Oncology
$4,100
Mar 14, 2025Janssen Biotech, Inc.
Mar 14, 2025
Consulting Fee
ERLEADA; AKEEGA · Oncology
$3,788
Oct 27, 2025Astellas Pharma US Inc
Oct 27, 2025
Consulting Fee
Padcev · Oncology
$2,100
Oct 3, 2025Janssen Biotech, Inc.
Oct 3, 2025
Consulting Fee
ERLEADA · Oncology
$1,263
Jun 5, 2025Janssen Scientific Affairs, LLC
Jun 5, 2025
Consulting Fee
ERLEADA · Oncology
$1,110
Feb 20, 2025Janssen Biotech, Inc.
Feb 20, 2025
Travel and Lodging
ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind
$684
Apr 4, 2025Janssen Biotech, Inc.
Apr 4, 2025
Consulting Fee
ERLEADA; AKEEGA · Oncology
$631
Mar 4, 2025Janssen Biotech, Inc.
Mar 4, 2025
Travel and Lodging
ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind
$263
Mar 4, 2025Janssen Biotech, Inc.
Mar 4, 2025
Travel and Lodging
ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind
$150
All 12 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Oct 27, 2025Astellas Pharma US Inc
Oct 27, 2025
Consulting Fee
Padcev · Oncology
$2,100
Oct 20, 2025Astellas Pharma Europe LTD
Oct 20, 2025
Travel and Lodging
Vyloy · Oncology · travel to Berlin, Germany
$17.90
Oct 3, 2025Janssen Biotech, Inc.
Oct 3, 2025
Consulting Fee
ERLEADA · Oncology
$1,263
Oct 1, 2025AstraZeneca Pharmaceuticals LP
Oct 1, 2025
Consulting Fee
IMFINZI · Oncology
$4,100
Jun 5, 2025Janssen Scientific Affairs, LLC
Jun 5, 2025
Consulting Fee
ERLEADA · Oncology
$1,110
Jun 4, 2025Merck Sharp & Dohme LLC
Jun 4, 2025
Compensation for services other than consulting (speaking, faculty)
WELIREG · ONCOLOGY
$4,270
Jun 4, 2025Merck Sharp & Dohme LLC
Jun 4, 2025
Travel and Lodging
WELIREG · ONCOLOGY · travel to Independence, OH
$25.00
Apr 4, 2025Janssen Biotech, Inc.
Apr 4, 2025
Consulting Fee
ERLEADA; AKEEGA · Oncology
$631
Mar 14, 2025Janssen Biotech, Inc.
Mar 14, 2025
Consulting Fee
ERLEADA; AKEEGA · Oncology
$3,788
Mar 4, 2025Janssen Biotech, Inc.
Mar 4, 2025
Travel and Lodging
ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind
$263
Mar 4, 2025Janssen Biotech, Inc.
Mar 4, 2025
Travel and Lodging
ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind
$150
Feb 20, 2025Janssen Biotech, Inc.
Feb 20, 2025
Travel and Lodging
ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind
$684

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Michigan →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $489,303 in research payments for these studies, mostly to the institutions running them.

  • A phase 2 multicohort openlabel multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48ADC alone or in combination with pembrolizumab in subjects with locallyadvanced unresectable or me…
    Seagen Inc.
  • A phase 2 multi cohort open label multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48 adc in subjects with HER2 expressing locally advanced unresectable or metastatic urothelial car…
    Seagen Inc.
  • Firstinhuman fih openlabel phase 1 dose escalation and expansion study designed to evaluate the safety tolerability pk pd and preliminary clinical activity of PF07826390 as a single agent or in combination treatment f…
    Pfizer Inc.
  • A phase 3 randomized doubleblind placebocontrolled study of mevrometostat PF06821497 with enzalutamide in metastatic castrationsensitive prostate cancer MEVPRO3
    Pfizer Inc.
  • Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
    AbbVie Inc. · Active, not recruiting · NCT06632951
  • A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle…
    Merck Sharp & Dohme LLC
  • A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
    Pfizer Inc.
  • A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder
    Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Ann Arbor

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 3, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1669855573. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.